DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2247453/omega-therapeutics-inc-omga-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2247453 Mar 28, 2024 - Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2256869/biogen-inc-biib-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2256869 Apr 17, 2024 - Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2257958/sage-sage-down-20-on-parkinson-s-study-missing-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257958 Apr 18, 2024 - Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo. 0

https://www.zacks.com/stock/news/2258435/what-s-in-store-for-biogen-biib-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258435 Apr 19, 2024 - Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate. 0

https://www.zacks.com/stock/news/2258367/gear-up-for-biogen-biib-q1-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2258367 Apr 19, 2024 - Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024. 0

https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301 Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease. 0

https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063 Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe. 0

https://www.zacks.com/stock/news/2203359/biogen-inc-biib-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2203359 Dec 28, 2023 - The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close. 0

https://www.zacks.com/stock/news/2221865/biogen-inc-biib-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2221865 Feb 06, 2024 - Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200 Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 0